Curcumin improves MMC-based chemotherapy by simultaneously sensitising cancer cells to MMC and reducing MMC-associated side-effects
- 26 May 2011
- journal article
- research article
- Published by Elsevier BV in European Journal Of Cancer
- Vol. 47 (14), 2240-2247
- https://doi.org/10.1016/j.ejca.2011.04.032
Abstract
No abstract availableKeywords
Funding Information
- National Science and Technology Major Project of China (2009ZX10004-601, 2009ZX09311-003)
- Shanghai Municipal Education Commission Project (08YZ54)
- E-Institutes of Shanghai Municipal Education Commission (E 03008)
This publication has 25 references indexed in Scilit:
- Chemopreventive Properties of CurcuminFuture Oncology, 2005
- Formation of DNA interstrand cross-links as a marker of Mitomycin C bioreductive activation and chemosensitivityEuropean Journal Of Cancer, 2005
- Mitomycin C induces apoptosis and caspase-8 and -9 processing through a caspase-3 and Fas-independent pathwayCell Death & Differentiation, 2002
- Curcumin (diferuloylmethane) induces apoptosis through activation of caspase-8, BID cleavage and cytochrome c release: its suppression by ectopic expression of Bcl-2 and Bcl-xlCarcinogenesis: Integrative Cancer Research, 2002
- Apoptosis: implications of basic research for clinical oncologyThe Lancet Oncology, 2001
- DIETARY CURCUMIN WITH CISPLATIN ADMINISTRATION MODULATES TUMOUR MARKER INDICES IN EXPERIMENTAL FIBROSARCOMAPharmacological Research, 1999
- Caspases: Enemies WithinScience, 1998
- Mitomycin C and Mitoxantrone in Anthracycline-Pretreated Advanced Breast Cancer PatientsAmerican Journal of Clinical Oncology, 1994
- Mitomycin C-induced renal toxicity, a dose-dependent side effect?European Journal of Cancer and Clinical Oncology, 1987
- Mitomycin C in Patients with Metastatic Breast Cancer Refractory to Hormone Therapy and ChemotherapyOncology, 1983